StreetInsider.com Unusual 11 Mid-Day Movers: NexMed, Inc. (Nasdaq: NEXM) 81.6% LOWER; announced that based on First Interpretable Results of Phase III clinical studies for NM100060, a topical application of terbinafine formulated with NexACT(R) for the treatment of onychomycosis, the decision has been taken not to submit a New Drug Application with the Food and Drug Administration at this time.

Cell Genesys, Inc. (Nasdaq: CEGE) 72.5% LOWER; terminated VITAL-2, the second of two Phase 3 clinical trials of GVAX immunotherapy for...